Anti-aging supplements rank by the outcome measured in randomized trials
Vitamin D, antioxidants and NAD+ absorb most of the demand, with very different levels of evidence. The first two have been tested in large randomized trials, with results largely negative outside deficiency. The third belongs mainly to cell biology and to short trials on surrogate markers. That hierarchy determines what deserves a workup and what belongs to comfort. Three categories then emerge: correcting a documented lack, supervised symptomatic use, and optimization with no identified loss.
In a person with no documented deficit, extra intake is eliminated, stored or used in pathways with no clinical benefit. The available trials show no effect on mortality or prevention in well-nourished adults. This finding does not condemn the sector: it separates correcting a lack from optimizing a function that is already assured. That distinction structures all advice, including on the anti-aging supplement category. Two exceptions belong to treating a disease rather than to prevention: high triglycerides on omega-3 at a therapeutic dose, and certain kidney or liver situations guided by a workup. Targeted supplementation is precisely that: a documented lack, a chosen dose, a review date.
Product quality varies from one manufacturer to another, and actual content can depart clearly from the label. Clinical trials often use molecular forms different from the products sold to the public. The opportunity cost, finally, is rarely expressed, although it is the largest item on the list. These three elements are checked before any arbitration: they determine the real value of the product purchased.
| Category | Available data | Practical conclusion | Level of evidence |
|---|---|---|---|
| Vitamin D | VITAL trial on more than 25,000 adults, benefit not found in a population without deficiency | Correction of a documented deficiency only | Established |
| Vitamin E | Primary prevention trials with no benefit on mortality, unfavorable signal in some groups | No indication for prevention in well-nourished people | Established |
| Synthetic antioxidants | Cochrane review: no prevention benefit, excess mortality in some categories | Not advised as self-medication | Established |
| Iron and vitamin B12 | Expected and documented benefit in case of a biological deficit | Prescription based on lab results, check of correction | Established |
| Omega-3 | Conflicting cardiovascular trials, benefit mainly expected when intake is insufficient | To discuss case by case | Probable |
| NAD+ and precursors | Cellular and animal studies, human trials on surrogate markers | Not demonstrated for mortality | Experimental |
| Creatine monohydrate | 3 to 5 g per day | Documented gain in strength and muscle mass, no effect on mortality | Established |
| Omega-3, EPA and DHA | 250 to 500 mg per day for prevention | Established effect on triglycerides, cardiovascular effect not confirmed | Probable |
| Vitamin K2, MK-7 form | 90 to 180 µg per day | Interaction with vitamin K antagonists, vascular effect not confirmed | Experimental |
Level of evidence for the main categories of anti-aging supplements in humans.
Vitamin D shows a documented benefit only in case of deficiency
In the VITAL trial, on more than 25,000 adults, supplementation reduced neither cancer incidence nor cardiovascular events outside deficiency. The expected benefit concerns people with little sun exposure, at high risk or with a documented deficit. Antioxidants, tested on the same logic, gave results that raise questions. NAD+ has not yet been assessed on these outcomes, for lack of long and large enough trials.
In an asymptomatic general population, systematic supplementation at a fixed dose has no justification documented by trials. In a person with a deficiency, correction has a documented effect on muscle function and bone balance, far from a longevity promise. An effect on mortality has never been demonstrated to date. That precision avoids two pitfalls: dogmatic refusal of a useful correction and generalized prescription without benefit.
Follow-up matters as much as the starting dose. The baseline value must be documented, a target consistent with the recommendations chosen, then a new check after three to six months. An insufficient response requires looking for the cause: poor absorption, unsuitable dose, partial adherence. This loop protects the person being supported, who understands the logic and avoids stacking other products. The most widespread schedule combines one 100,000 IU ampoule as a single dose, repeated at one, two or three month intervals depending on the baseline value. It avoids daily intake over several years for a value reached in a few weeks.

Antioxidants bring no benefit in preventing mortality
Synthetic antioxidants have been the subject of unfavorable syntheses. The Cochrane review concluded on the absence of benefit in preventing mortality, and on a possible increase in certain categories of patients. NAD+ and its precursors rest on work in cell culture and in animals. Their human trials concern surrogate markers, not mortality.
The argument most often opposed to these products, their action on oxidative stress, is real at the cellular level. A metabolic pathway modulated in the laboratory says nothing about what happens to a healthy person. That is the reasoning the level of evidence allows us to discuss with the person being supported. A diet rich in plant foods provides these compounds in a context that protects them from digestive oxidation. It delivers them with fiber, associated polyphenols and minerals, which the isolated molecule does not reproduce. That difference in context explains why a deficiency can justify a molecule, and never a diet that is already diversified.
The same caution applies to molecules sold as blockers of cellular aging. A molecule published this year has often undergone no randomized trial, in small cohorts or without a control group. High-dose vitamin E and beta-carotene illustrate this risk, with unfavorable signals in smokers. The useful question remains whether a trial on a relevant clinical outcome exists, for that molecule. The case of cocoa and green tea polyphenols is different: a randomized trial on a cocoa extract rich in flavanols reports a fall in cardiovascular mortality, an effect not consistently found for total mortality.

NAD+ remains experimental and its trials use surrogate markers
The mechanism is solid: these molecules take part in cellular energy production, and their age-related decline is observed in several animal tissues. In humans, trials are short, involve a few hundred subjects at most and use surrogate markers. None assesses mortality, chronic disease incidence or loss of function, the outcomes of a longevity approach. A favorable marker does not guarantee a favorable clinical consequence. Vitamin B3 or niacin, often added to formulations, does raise NAD+ but causes flushes and changes several risk factors with no demonstrated clinical benefit.
A safety argument adds to the efficacy argument. Most marketed products have undergone no long-term tolerance trial beyond a few weeks. Available data concern healthy subjects, in small numbers, and ignore interactions with treatments. Caution is all the more warranted because a product with no demonstrated benefit offers no balance between risk and return. Side effects reported over a few weeks are most often moderate, which explains wide adoption while data beyond two years are missing. It is a classic risk profile: few acute effects, no long-term data, and public uptake that goes far beyond the populations tested.
An honest answer does not devalue the demand, it moves it. The best documented determinants of longevity remain physical activity, muscle strength, diet, sleep and risk factors. A budget devoted to one of them produces a measurable benefit, where the cutting-edge product remains without an assessed outcome. The professional can specify what would change that opinion: a randomized trial on a health outcome.

Overdose, interactions and opportunity cost bound any supplementation
The best documented risk is drug interaction: vitamin D or K with anticoagulants, iron with certain treatments. High-dose antioxidants and plant-based products remain poorly documented over the long term, and must be discussed with any treatment. None of these limits calls into question the value of a correction, but all impose a documented framework. The list of products consumed, including without advice, is part of the follow-up file. Vitamin K2 changes the effect of vitamin K antagonists and can destabilize well-balanced treatment, so any introduction must be reported to the prescriber. Iron reduces the absorption of zinc, calcium and quinolones, which requires spacing doses by two hours. Vitamin D combined with a thiazide diuretic raises the risk of hypercalcemia, which justifies monitoring in older adults.
Overdose is not a theoretical risk. High doses of certain vitamins remain harmful over the long term, even when well tolerated in the short term. Splitting doses does not improve this risk in any documented way. Stopping and then resuming at the first discomfort often passes for adaptation, when it is an undocumented dose fluctuation.
Opportunity cost is the most expensive risk and the most rarely expressed. Every product bought takes resources away from what has evidence: diet, physical activity, sleep. Three daily capsules cost about two hundred euros a year, for an effect that is most often undocumented. Addressing that cost from the first request avoids a gradual accumulation of products without a goal.

Targeted supplementation is documented, dosed and reviewed at three months
Targeted supplementation is decided in three steps, which makes follow-up legible. The first step is the written justification: documented lack, baseline value, chosen target and reference used. The second step is the lowest prescription compatible with that target, with a stated duration and a limited number of products. The third step is the review at three months, which decides on continuation, adjustment or stopping.
This review is prepared with a few simple elements. Tolerance, actual adherence, the result of the new test if a check is planned, and the other products consumed since the last appointment must be recorded. Stopping is decided on explicit criteria: normalized result with no identified need, absence of benefit despite correct adherence. A correction obtained and stabilized deserves a discussed stop, not treatment continued by habit. A review date entered in the file prevents supplementation from extending from one consultation to the next. Populations at risk of dosing errors are identifiable: kidney failure, impaired liver function, older adults on four or more treatments, pregnancy.
This approach also changes the working relationship. The person understands that a refused recommendation rests on data, not on a refusal of care. They can then spontaneously bring back products bought elsewhere, which becomes usable information for follow-up. The time gained on stacking is found again in following the files where evidence exists.

Sources
- 1.Manson JE, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease (VITAL). N Engl J Med. 2019.
- 2.Bjelakovic G, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012.
- 3.Guarente L, et al. Human trials exploring anti-aging medicines. Cell Metab. 2024.
- 4.Partridge L, et al. The quest to slow ageing through drug discovery. Nat Rev Drug Discov. 2020.
- 5.Shaito A, et al. Potential adverse effects of resveratrol: a literature review. Int J Mol Sci. 2020.
- 6.Dutta S, et al. Metformin: a review of potential mechanism and therapeutic utility beyond diabetes. Drug Des Devel Ther. 2023.
- 7.Abdellatif M, et al. Anti-ageing interventions for the treatment of cardiovascular disease. Cardiovasc Res. 2025.
Reading studies is one thing, turning them into a plan is another
The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.
11 modules, €2,200. Enrol
Continue reading
Benjamin Sant
Co-founder of the School of Longevity
Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.
This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.
